Bio
My research interest lies in liquid biopsy and early cancer diagnostics, e.g. development of bioassay for detection of cancer biomarkers (proteins and genes) and single-cell research. As well as the integration of 3D-printed microfluidics.
Honors & Awards
-
Charles E. Waring Award, Department of Chemistry, University of Connecticut (2016-2017)
Professional Education
-
Bachelor of Science, Fudan University (2016)
-
Doctor of Philosophy, University of Connecticut (2021)
-
BS, Fudan University, Shanghai, China, Chemistry (2016)
-
PhD, University of Connecticut, USA, Analytical Chemistry (2021)
All Publications
-
Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells.
Nature biotechnology
2023
Abstract
Genome sequencing studies have identified numerous cancer mutations across a wide spectrum of tumor types, but determining the phenotypic consequence of these mutations remains a challenge. Here, we developed a high-throughput, multiplexed single-cell technology called TISCC-seq to engineer predesignated mutations in cells using CRISPR base editors, directly delineate their genotype among individual cells and determine each mutation's transcriptional phenotype. Long-read sequencing of the target gene's transcript identifies the engineered mutations, and the transcriptome profile from the same set of cells is simultaneously analyzed by short-read sequencing. Through integration, we determine the mutations' genotype and expression phenotype at single-cell resolution. Using cell lines, we engineer and evaluate the impact of >100 TP53 mutations on gene expression. Based on the single-cell gene expression, we classify the mutations as having a functionally significant phenotype.
View details for DOI 10.1038/s41587-023-01949-8
View details for PubMedID 37697151
View details for PubMedCentralID 8018281
-
Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
Blood
2023
Abstract
An early event in the genesis of follicular lymphoma (FL) is the acquisition of new glycosylation motifs in the B cell receptor (BCR) due to gene rearrangement and/or somatic hypermutation. These N-linked glycosylation motifs (N-motifs) contain mannose-terminated glycans and can interact with lectins in the tumor microenvironment, activating the tumor BCR pathway. N-motifs are stable during FL evolution suggesting that FL tumor cells are dependent on them for their survival. Here, we investigated the dynamics and potential impact of N-motif prevalence in FL at the single cell level across distinct tumor sites and over time in 17 patients. While most patients had acquired at least one N-motif as an early event, we also found (i) cases without N-motifs in the heavy or light chains at any tumor site or timepoint and (ii) cases with discordant N-motif patterns across different tumor sites. Inferring phylogenetic trees for the patients with discordant patterns, we observed that both N-motif-positive and N-motif-negative tumor subclones could be selected and expanded during tumor evolution. Comparing N-motif-positive to N-motif-negative tumor cells within a patient revealed higher expression of genes involved in the BCR pathway and inflammatory response, while tumor cells without N-motifs had higher activity of pathways involved in energy metabolism. In conclusion, while acquired N-motifs likely support FL pathogenesis through antigen-independent BCR signaling in most FL patients, N-motif-negative tumor cells can also be selected and expanded and may depend more heavily on altered metabolism for competitive survival.
View details for DOI 10.1182/blood.2023020360
View details for PubMedID 37683139